Half-year report · HY
4272.TEDINET S100X0X1
Period2025-04-01 → 2025-09-30
Filed2025-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥113.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥222.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥109.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥10.6bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥11.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥10.8bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥22.3bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥11.7bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥16.6bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥8.6bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥11.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥17.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥11.7bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥6.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥391.9bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥373.7bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥356.6bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥122.7bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥105.2bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥269.2bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥268.5bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥264.2bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥68.8bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥55.4bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥71.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥57.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥52.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥64.8bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥18.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥25.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥14.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥27.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥16.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥3.7bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥9.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥75.07 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥107.17 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.21 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥75.07 | 2025-04-01 → 2025-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥107.16 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥36.2 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 68.4% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.8% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥113m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥113m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥4.9bn |
| Fine Chemicals Business Unitreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥34.4bn |
| Fine Chemicals Business Unitreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥34.2bn |
| Fine Chemicals Business Unitreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥106m |
| Fine Chemicals Business Unitreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥5.0bn |
| Life Science Business Unitreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥33.1bn |
| Life Science Business Unitreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥33.1bn |
| Life Science Business Unitreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥0 |
| Life Science Business Unitreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥5.3bn |
| Mobility And Imaging Business Unitreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥46.3bn |
| Mobility And Imaging Business Unitreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥46.3bn |
| Mobility And Imaging Business Unitreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6m |
| Mobility And Imaging Business Unitreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥5.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥113.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥113.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥113m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥15.5bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥87m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥87m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥4.4bn |
| Fine Chemicals Business Unitreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥32.7bn |
| Fine Chemicals Business Unitreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥32.6bn |
| Fine Chemicals Business Unitreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥87m |
| Fine Chemicals Business Unitreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥4.9bn |
| Life Science Business Unitreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥30.5bn |
| Life Science Business Unitreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥30.5bn |
| Life Science Business Unitreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| Life Science Business Unitreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| Mobility And Imaging Business Unitreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥46.0bn |
| Mobility And Imaging Business Unitreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥46.0bn |
| Mobility And Imaging Business Unitreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥7.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥109.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥109.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥87m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥15.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 562
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 109109000000 | JPY |
| Revenues from external customers | Prior1InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1InterimDuration | 109109000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 87000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_jpcrp040300-ssr_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 0 | JPY |
| Transactions with other segments | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 87000000 | JPY |
| Transactions with other segments | Prior1InterimDuration_ReconcilingItemsMember | -87000000 | JPY |
| Transactions with other segments | Prior1InterimDuration | － | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 45996000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 32705000000 | JPY |
| Net sales | Prior1InterimDuration_jpcrp040300-ssr_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 30495000000 | JPY |
| Net sales | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 109196000000 | JPY |
| Net sales | Prior1InterimDuration_ReconcilingItemsMember | -87000000 | JPY |
| Net sales | Prior1InterimDuration | 109109000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 7025000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 4904000000 | JPY |
| Operating income | Prior1InterimDuration_jpcrp040300-ssr_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 3589000000 | JPY |
| Operating income | Prior1InterimDuration_TotalOfReportableSegmentsAndOthersMember | 15519000000 | JPY |
| Operating income | Prior1InterimDuration_ReconcilingItemsMember | -4358000000 | JPY |
| Operating income | Prior1InterimDuration | 11160000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 46269000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 34245000000 | JPY |
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 33060000000 | JPY |
| Revenues from external customers | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 113575000000 | JPY |
| Revenues from external customers | InterimDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | InterimDuration | 113575000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 6000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 106000000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 0 | JPY |
| Transactions with other segments | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 113000000 | JPY |
| Transactions with other segments | InterimDuration_ReconcilingItemsMember | -113000000 | JPY |
| Transactions with other segments | InterimDuration | － | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 46276000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 34352000000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 33060000000 | JPY |
| Net sales | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 113689000000 | JPY |
| Net sales | InterimDuration_ReconcilingItemsMember | -113000000 | JPY |
| Net sales | InterimDuration | 113575000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 5208000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 4965000000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 5316000000 | JPY |
| Operating income | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 15490000000 | JPY |
| Operating income | InterimDuration_ReconcilingItemsMember | -4871000000 | JPY |
| Operating income | InterimDuration | 10618000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-11-12 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第169期中(自 2025年４月１日 至 2025年９月30日) |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |